Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Century Therapeutics Inc
IPSCCurrent price
1.26 USD
-0.09 USD (-6.67%)
Last closed
1.41 USD
Company
www.centurytx.com
ISIN
US15673T1007
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
122 441 768 USD
Yield for 12 month
-3.08 %
1Y
3Y
5Y
10Y
15Y
IPSC
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. Address: 25 North 38th Street, Philadelphia, PA, United States, 19104
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
9.67 USDP/E ratio
–Dividend Yield
–Current Year
+2 235 000 USD
Last Year
+5 199 000 USD
Current Quarter
+791 000 USD
Last Quarter
+771 000 USD
Current Year
-10 809 000 USD
Last Year
-4 872 000 USD
Current Quarter
-2 506 000 USD
Last Quarter
-2 691 000 USD
Key Figures IPSC
1 year
3 years
5 years
10 years
EBITDA
-117 932 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-20.9 %
PEG Ratio
–
Return On Equity TTM
-62.61 %
Wall Street Target Price
9.67 USD
Revenue TTM
2 684 000 USD
Book Value
2.31 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
434.5 %
Dividend Yield
–
Gross Profit TTM
5 199 000 USD
Earnings per share
-1.83 USD
Diluted Eps TTM
-1.83 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics IPSC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IPSC
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation IPSC
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
1.9555
Price Sales TTM
45.6191
Enterprise Value EBITDA
0.0752
Price Book MRQ
0.6301
Financials IPSC
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators IPSC
For 52 weeks
1.14 USD
5.51 USD
50 Day MA
1.51 USD
Shares Short Prior Month
3 492 280
200 Day MA
2.8 USD
Short Ratio
9.08
Shares Short
3 325 333
Short Percent
4.81 %
BeatStart